Contraception, endometriosis, menopausal vasomotor symptoms; hormonally-dependent, recurrent breast cancer in post-menopausal women. Adjunctive &/or palliative treatment of recurrent &/or metastatic endometrial or renal carcinoma.
IM Contraception 150 mg every 3 mth. Endometriosis 50 mg wkly or 100 mg every 2 wk for at least 6 mth. Menopausal vasomotor symptoms 150 mg every 12 wk. Recurrent &/or metastatic endometrial or renal cancer Initially 400-1,000 mg wkly then maintain at 400 mg mthly. Hormonally-dependent, recurrent breast cancer in postmenopausal women Initially 500 mg daily for 28 days then maintain at 500 mg twice wkly.
Not a protection against HIV infection or other STDs. Not recommended in patients w/ history of venous thromboembolism (VTE). Unexpected vag bleeding, degree of fluid retention, history of clinical depression treatment, diabetic patients; diplopia, sudden partial or complete loss of vision, proptosis; loss of bone mineral density; osteoporotic risk factors eg, chronic alcoholism/tobacco use, chronic use of drugs reducing bone mass eg, anticonvulsants or corticosteroids, low BMI, eating disorder eg, anorexia nervosa or bulimia, metabolic bone disease, strong family history of osteoporis; breast & ovarian cancer; increased risk of CV events eg, MI, CHD, stroke, VTE; CAD; stroke; pulmonary embolism; dementia. Ensure adequate calcium & vit D intake. Hepatic insufficiency. Lactation. Pre-menarche childn.
Manage Account
Change Password
Sign Out
